Related Experiment Video

Updated: Mar 30, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance

Srivatsava Naidu1, Michela Garofalo1

  • 1Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester , Manchester , UK.

Frontiers in Medicine
|November 20, 2015
PubMed

Insights

MicroRNAs (miRNAs) are key regulators in lung cancer, influencing both cancer development and resistance to chemotherapy. Understanding their roles offers new strategies for effective cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer remains a leading cause of cancer-related mortality with limited treatment options.
  • Therapeutic success is often hindered by the rapid development of drug resistance.
  • MicroRNAs (miRNAs), small non-coding RNAs, play a critical role in gene regulation and have emerged as significant factors in cancer biology.

Purpose of the Study:

  • To review recent findings on the dual role of miRNAs as oncomiRs and tumor suppressors in lung cancer.
  • To discuss the involvement of miRNAs in various drug resistance mechanisms in lung cancer.
  • To highlight the potential of targeting miRNAs for novel combinatorial therapeutic strategies.

Main Methods:

  • Literature review of recent preclinical and clinical studies.
  • Analysis of miRNA regulatory functions in gene expression.
  • Examination of miRNA involvement in cancer development and drug resistance pathways.

Main Results:

  • miRNAs are confirmed to be crucial in carcinogenesis and the acquisition of chemoresistance.
  • Modulating miRNA expression can enhance the efficacy of chemotherapeutic drugs in preclinical models.
  • miRNAs function as both oncogenes (oncomiRs) and tumor suppressors in lung cancer.

Conclusions:

  • Comprehensive understanding of miRNA roles in lung cancer drug resistance is essential.
  • Targeting miRNAs presents novel opportunities for developing effective combination therapies.
  • Further research into miRNA modulation may improve treatment outcomes for lung cancer patients.
Keywords:
cancer therapychemoresistancedrug responselung cancermicroRNAs

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

844
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.3K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K
MicroRNAs01:22

MicroRNAs

12.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K